Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Toxin A Treatment Of Overactive Corrugator Supercilii In Thyroid Eye Disease

J. Olver
Published 1998 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND/AIM Patients with thyroid eye disease with upper eyelid retraction often develop overaction of the accessory muscles of eyelid closure, the glabellar muscles corrugator supercilii and procerus. The resultant glabellar furrowing (frown lines) contributes to the typical thyroid facies. The aim of this study was to evaluate the use of botulinum toxin A reversible chemodenervation of the glabellar muscles as adjunctive treatment in the rehabilitation of patients with thyroid eye disease. METHODS 14 patients (13 females) ages 39–76 years (mean 52) with inactive thyroid eye disease and associated medial eyebrow ptosis and prominent glabellar frown lines were recruited. All patients had a history of upper eyelid retraction. Each patient was treated with a single botulinum toxin injection (Dysport 0.2 ml, 40 units) into each corrugator supercilii and sometimes procerus muscles as an outpatient procedure. The effectiveness and acceptability of the treatment was assessed clinically and from a patient questionnaire. RESULTS The injections were tolerated by 13/14 (93%) patients. There was resultant flattening of the glabellar region and improvement of medial eyebrow contour in all patients, with onset of paralysis within 1 week. All patients reported a subjective improvement in appearance. Side effects included one patient (7%) with reversible partial ptosis. The beneficial effect lasted 4–6 months, with a gradual return of function. Repeat treatment was indicated where there was persistent upper eyelid retraction and protractor overaction. CONCLUSION Botulinum toxin A chemodenervation of the glabellar muscles in these patients was effective and acceptable. Chemodenervation should be considered in the rehabilitation of patients with thyroid eye disease where there is upper eyelid retraction and overacting protractors resulting in a thyroid frown. Once the eyelid retraction has been successfully treated by surgery, the need for further glabella muscle chemodenervation is considerably reduced.
This paper references
Local side effects of botulinum toxin injections.
J. Patrinely (1988)
10.1001/ARCHDERM.1989.01670200066010
The microanatomical basis of facial frown lines.
G. Piérard (1989)
10.1136/bjo.71.9.664
Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections.
J. Elston (1987)
10.3327/jaesj.26.686
An interim report
D. Freidel (1986)
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short-and long-term, local and systemic eVects
J J Dutton (1996)
10.1001/ARCHOTOL.1993.01880210108015
Botulinum toxin for the treatment of hyperfunctional lines of the face.
A. Blitzer (1993)
Local side eVects of botulinum toxin injections. Facial dyskinesias
J R Patrinely (1988)
Long term results of treatment of idiopathic blepharospasm with botulinum toxin injection
J S Elston (1987)
10.1016/S0002-9394(14)77954-1
The use of botulinum toxin in blepharospasm.
N. Shorr (1985)
10.1016/S0161-6420(96)30644-1
The use of botulinum A toxin to ameliorate facial kinetic frown lines.
J. Foster (1996)
10.1097/00006534-199506000-00005
Anatomy of the Forehead Muscles: The Basis for the Videoendoscopic Approach in Forehead Rhytidoplasty
A. Abramo (1995)
10.1001/ARCHOPHT.1985.01050030043017
Botulinum A toxin injection as a treatment for blepharospasm.
A. Scott (1985)
10.1016/S0039-6257(97)81995-9
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects.
J. Dutton (1996)
10.1016/0002-9394(85)90797-4
Sequelae of botulinum toxin injection.
R. Lingua (1985)
10.1097/01.PRS.0000150149.74749.55
Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis.
R. P. Clark (1989)
10.1002/MDS.870020402
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
M. Brin (1987)
The fasciae and muscles of the head
(1973)
10.1017/S0317167100026159
Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion.
J. Carruthers (1987)
10.1001/ARCHOPHT.1982.01030030989019
The anatomy of eyebrow ptosis.
B. Lemke (1982)
10.1097/00006534-198807000-00010
The superficial musculoaponeurotic system of the nose.
A. Létourneau (1988)
Local side e V ects of botulinum toxin injections
Patrinely (1988)
10.1097/00006534-199404001-00003
Aesthetic Indications for Botulinum Toxin Injection
B. Guyuron (1994)
10.1016/0002-9394(85)90228-4
Treatment of blepharospasm with botulinum toxin.
E. A. Tsoy (1985)
10.1038/EYE.1987.93
Botulinum toxin A induced protective ptosis
G. Adams (1987)
10.1111/J.1524-4725.1992.TB03295.X
Treatment of glabellar frown lines with C. botulinum-A exotoxin.
J. Carruthers (1992)
Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study.
J. Taylor (1991)
The anchor subperiosteal forehead flap
O M Ramirez (1995)
10.1097/00006534-198903000-00028
Blepharospasm and its treatment, with emphasis on the use of botulinum toxin.
G. Borodic (1989)
10.1136/jnnp.51.6.767
Blepharospasm: a review of 264 patients.
F. Grandas (1988)
10.1097/00002341-198601060-00005
Treatment of Hemifacial Spasm with Botulinum A Toxin: Results and Rationale
R. Gonnering (1986)
Botulinum toxin injection of eye muscles to correct strabismus.
A. B. Scott (1981)
10.1097/00006534-199505000-00006
The Anchor Subperiosteal Forehead Lift
O. Ramírez (1995)
10.1016/S0161-6420(88)32976-3
Treatment of sixth nerve palsy in adults with combined botulinum toxin chemodenervation and surgery.
R. Fitzsimons (1988)
Local side e V ects of botulinum toxin injections . Facial dyskinesias
Patrinely
Botulinum - A toxin in the treatment of craniocervical muscle spasms : shortand long - term , local and systemic e V ects
JJ Dutton (1996)
10.1136/BJO.72.5.361
Treatment of senile entropion with botulinum toxin.
J. Clarke (1988)
10.3109/01676839509150044
The use of botulinum toxin for lower lid entropion
H. Hoh (1995)
Botulinum toxin for the treatment of hyperfunction lines of the face
A Blitzer (1993)
The fasciae and muscles of the head
R Warwick (1973)
The superficial musculoaponeu - rotic system of the nose
A Letourneau (1988)
Localised injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
M F Brin (1988)
Botulinum - A toxin in the treatment of craniocer - vical muscle spasms : short - and long - term , local and systemic e V ects
JJ Dutton (1996)
10.1097/00006534-199407000-00009
Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled Study
M. Keen (1994)
10.1016/S0161-6420(86)33641-8
Treatment of facial spasm with botulinum toxin. An interim report.
B. Frueh (1986)
10.1001/ARCHOPHT.1984.01040031184014
Treatment of blepharospasm with botulinum toxin. A preliminary report.
B. Frueh (1984)



This paper is referenced by
10.1034/J.1600-0420.2001.790608.X
Thyroid associated ophthalmopathy: botulinum toxin A in the treatment of upper eyelid retraction--a pilot study.
F. Träisk (2001)
10.1007/978-1-4615-4647-4_3
Assessment of disease severity
J. Garrity (2000)
10.1076/orbi.20.4.281.2608
Graves' ophthalmopathy through the eyes of the patient: A state of the art on health-related quality of life assessment
C. Terwee (2001)
Nuevas indicaciones en el tratamiento mediante la toxina botul??nica tipo A en cosm??tica: Boca y cuello:
M. Matilde M. Sp sito (2004)
10.1007/978-981-32-9220-8_17
Periorbital Aesthetic Considerations in Thyroid Eye Disease
M. N. Naik (2020)
10.1590/s0004-27302006000500014
artigo original Análise Morfométrica da Fenda Palpebral de Pacientes Com Oftalmopatia Distireóidea Antes e Após Aplicação de Toxina Botulínica Tipo A
Patrícia Grativol Costa (2006)
Chapter 3 Assessment of disease severity
J. Garrity (2000)
10.1097/PRS.0b013e3181b5641b
Evaluation of Variable-Dose Treatment with a New U.S. Botulinum Toxin Type A (Dysport) for Correction of Moderate to Severe Glabellar Lines: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
M. Kane (2009)
10.1111/J.1524-4725.2005.31072
Treatment of Nasal Wrinkles with Botulinum Toxin
B. Tamura (2005)
10.1111/j.1524-4725.2011.02075.x
Time to Onset of Response of AbobotulinumtoxinA in the Treatment of Glabellar Lines: A Subset Analysis of Phase 3 Clinical Trials of a New Botulinum Toxin Type A
J. Schlessinger (2011)
10.1007/978-1-4615-1447-3
Thyroid Eye Disease
S. Melmed (2001)
10.1097/00055735-199910000-00012
Surgical management of Graves orbitopathy.
D. Meyer (1999)
10.1097/00006534-200310001-00013
New Indications for Botulinum Toxin Type A in Cosmetics: Mouth and Neck
M. M. M. S. sito (2003)
10.1016/j.asj.2009.09.012
An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
L. Baumann (2009)
10.1001/archfacial.2009.5
Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
R. Moy (2009)
10.1186/2045-5380-4-11
Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: preliminary findings from an A-B-A design
M. Kim (2014)
10.1016/S1043-2760(02)00622-7
Graves’ ophthalmopathy: a rational approach to treatment
W. Wiersinga (2002)
SUBCONJUNCTIVAL BOTULINUM TOXIN INJECTION FOR MANAGEMENT OF UPPER AND LOWER LID RETRACTION ASSOCIATED WITH THYROID OPHTHALMOPATHY
M. Razavi (2006)
10.1590/S0004-27302006000500014
[Morphometric analysis of the palpebral fissure in patients with thyroid-related disfunction before and after application of botulinum toxin].
Patrícia Grativol Costa (2006)
10.1111/j.1524-4725.2009.01235.x
Randomized, Placebo‐Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines: Efficacy and Safety
F. Brandt (2009)
Efficacy of subcision with Nokor needle 18 in the correction of glabella furrow in Mexican population. A pilot study
os Luz Tania Simancas-Llanos (2015)
10.1097/01.iio.0000167165.25649.e7
Advanced Functional Oculofacial Indications of Botulinum Toxin
C. Lee (2005)
10.1007/s00266-002-1491-2
New Indications for Botulinum Toxin Type A in Treating Facial Wrinkles of the Mouth and Neck
M. Sposito, (2002)
10.1097/00006534-200208000-00037
New Indications for Botulinum Toxin Type A in Cosmetics: Mouth and Neck
M. M. Spósito (2002)
10.1016/j.asj.2009.09.010
An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Mark G. Rubin (2009)
10.1097/00002341-200103000-00003
Glabellar Rhytids in Thyroid-Associated Orbitopathy
N. D. Saks (2001)
10.1097/01.PRS.0000124409.17493.B7
Nuevas indicaciones en el tratamiento mediante la toxina botulínica tipo A en cosmética: Boca y cuello
M. M. M. Spósito (2004)
10.1016/J.SURVOPHTHAL.2006.10.003
Botulinum toxin in ophthalmology.
J. Dutton (2007)
Eficacia de la subincisión con aguja Nokor 18 en la corrección del surco interciliar en población mexicana. Estudio piloto
Luz Tania Simancas-Llanos (2015)
Graves' opthalmopathy through the eyes of the patient assessment of health-related quality of life
C. Terwee (2000)
10.1016/j.jaad.2009.03.049
Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
G. Monheit (2009)
10.1016/J.OPHTHA.2005.03.021
Cosmetic oculofacial applications of botulinum toxin: a report by the American Academy of Ophthalmology.
S. Kaltreider (2005)
See more
Semantic Scholar Logo Some data provided by SemanticScholar